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ABSTRACT
Epstein-Barr virus (EBV) reactivation, indicated by
induction of EBV early antigens from latently infected
lymphoid cell lines by phorbol esters, is inhibited by
retinoic acid (RA). Viral reactivation, which is triggered
by the immediate-early BZLF-1 (Z) viral gene product,
is repressed by retinoic acid receptors (RARs) RARa
and RXRa. These proteins negatively regulate Z-
mediated transactivation of the promoter for an EBV
early gene product, early antigen-diffuse (EaD). Here
we confirm a direct physical interaction between the
APi-like protein Z and RXRa and map the domains of
interaction in the Z protein and RXRa. The domain
required for homodimerization of Z is separate from
that required for its interaction with RXRac. Z also has
the effect of repressing activation of an RAR-respon-
sive cellular promoter (BRE). Point mutants in the
dimerization domain of Z unable to interact with RXRa
do not repress RXRa-mediated transactivation of BRE,
the promoter for RAR3, which suggests that interac-
tion between the two proteins is required for this
repressor effect. The domain of RXRa required for
interaction with Z has been mapped, and is again
separate from that required for homodimerization.
These results indicate that a 'cross-coupling' or direct
interaction between Z and RARax and RXRa can
modulate the reactivation of latent EBV infection and
suggest that, reciprocally, the viral protein Z may
influence cellular regulatory pathways.
INTRODUCTION
Epstein-Barr virus (EBV) is a human herpesvirus that infects
lymphocytes and certain epithelial cells and is associated with
several malignancies. EBV is prominently associated with B-cell
lymphomas and rare T-cell malignancies as well as nasopharyn-
geal and parotid carcinomas. In oral hairy leukoplakia in
immunosuppressed persons, EBV replicates rapidly in the
differentiated epithelial cells of the tongue. Infection of B-lym-
phocytes is predominantly latent and results in lymphoprolifer-
ation. Infection of epithelial cells can be latent, as in
nasopharyngeal carcinoma, but usually leads to complete viral
replication resulting in cytolysis. In cell culture, several factors
can induce the latent virus into its productive phase, such as TPA,
sodium butyrate, surface anti-IgG cross-linking and nucleoside
analogs, all of which mediate their effect through the EBV
immediate-early BZLF-1 protein Z (also called ZEBRA, Zta,
EB-1). Z serves as a trigger to disrupt latency by initiating a
cascade of events that includes transactivation of other regulatory
proteins, BRLF-1 (R) and BMLF-1 (M), which together with Z
activate early genes; DNA replication and late gene expression
follow (1-3). Therefore, Z is a central target for interaction with
cellular proteins, some of which may abrogate Z-mediated
transactivation and potentially curb cytolysis.
Z, a member of the basic leucine-zipper family, transactivates
the viral early promoters by binding to upstream binding sites,
Z-response elements (ZREs) (1-9) that are similar and sometimes
identical to API sites (1,2,5,6,8-11). Interaction of cellular or
viral factors results in modulation of Z action to produce
synergistic transactivation or repression of early promoters. For
instance, the viral immediate-early protein R can synergize with
Z to transactivate early promoters (12) as does the cellular factor,
c-myb (13). Recently p53 and p65 have been shown to interact
with Z (14,15) and repress Z-mediated transactivation. Thus there
are several cellular regulators, some of which tend to counter
reactivation of this normally latent infection. In addition, a
recently described viral gene product, RAZ, which acts as a
transdominant repressor, can abort Z-mediated reactivation in
latently infected cells (16).
We have previously shown that the retinoic acid receptor,
RARa, and the retinoid X receptor, RXRx, repress Z-mediated
transactivation of the EBV early promoter, BMRF1 (17). RARs
and RXRs are members of the steroid hormone receptor
superfamily that differ in their ligand-binding domains (18).
Retinoic acid (RA) is the ligand for RAR whereas a metabolic
derivative of RA, 9-cis RA, is the ligand for the RXR receptor
(19). The receptors form homo and heterodimers which transcrip-
tionally activate target genes by binding to cis-acting elements
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called retinoic-acid response elements (RARE). While RARs and
RXRs are effective activators of some genes, they are also known
to repress several genes by different mechanisms (20,2 1).
Retinoic acid receptors not only repress activation of viral genes
by Z, but conversely, Z can also repress RARa and RXRa-
mediated transactivation of a cellular promoter (BRE) for the
RAR, gene. RXRa prevents Z from binding to an APl site in the
BMRF1 promoter and, reciprocally, Z inhibits RARx from
binding to a RARE in the RAR, promoter (17). Thus these
cellular factors can modulate viral activators, and conversely, the
viral API-like protein can itself affect cellular circuitry. Although
steroid hormone receptors, particularly RAR and glucocorticoid
receptor (GR), have an antagonistic relation with the API family
of proteins (22), both inhibiting API from binding to its cognate
DNA sequences (22), a direct physical interaction between the
zinc-finger-containing retinoic acid receptors and the leucine-
zipper-containing API protein(s) has not been shown.
Here we demonstrate such an interaction between both RXRa
andRARa and the API-like Z protein in vitro with glutathione-S-
transferase fusion proteins. We have mapped the domain in
RXRx that interacts with Z and found that it is different from that
required for homodimerization ofRXRa. Using point mutations
in the dimerization domain of Z, we demonstrate that the region
required for homodimerization ofZ is separate from that required
for interaction with RXRa. Corroborating the in vitro data are the
functional effects observed in vivo, namely, that point mutants of




The plasmid pGEX-Z was a generous gift fromDavid Gutsch and
Shannon Kenney (University of North Carolina at Chapel Hill).
The clones pGEX-RXRa, pRshRARa and pRshRXRa were
generous gifts from Ronald Evans. The plasmids with point
mutations in the Z open reading frame (ORF) used to make in
vitro-translated proteins were generous gifts from Eric Flemington.
All the Z mutants were subcloned into pHD1013 for use in
transfected cells. The RXRa ORF was subcloned as an EcoRI
fragment into pBS (Stratagene). The GST-Z fusion protein
contains the entire Z ORF cloned downstream of the glutathione
transferase gene into the pGEX3X vector (Pharmacia). Con-
structs containing deletions in the Z ORF removing either 86
N-terminal amino acids (ZA 1-86), amino acids 25-29 (ZA
25-29), amino acids 140-227 (ZA 140-227) or amino acids
200-227 (ZA 200-227) as well as BMRE1-CAT (gifts from
Shannon Kenney) were also used (13).
GST-fusion-protein affinity chromatography
The GST-Z and GST-RXRa were expressed as previously
described (14,23). The ability of 35S-labelled in vitro-translated
RXRa to interact with GST-Z was analyzed by affinity chroma-
tography. GST-Z fusion protein bound to beads was incubated
with radiolabelled RXRa in reaction buffer (17) for 1 h at 37°C,
washed, pelleted and boiled in Laemmli buffer. Bound proteins
were resolved by SDS/PAGE on 10% gels and visualized by
DNA transfections
Plasmid DNA was amplified in Escherichia coli and purified
through two sequential cesium chloride gradients or by Qiagen
columns. DNA was transfected into EBV- lymphoblastoid cells
(Louckes) by electroporation (24) using 10 pg DNA and 107
cells/condition. The cells were shocked at 1500 V with a Zapper
electroporation unit (Medical Electronics Shop, University of
Wisconsin). Twenty-four hours before transfections, cells were
transferred to phenol-red-free RPMI 1640 medium supplemented
with 5% (v/v) charcoal-stripped serum (CSS). Transfections were
done in complete RPMI-1640 (10% v/v FCS), and then cells were
returned to medium containing 5% CSS and incubated for 48 h at
37°C in 5% CO2. Retinoic acid (RA) (1 tM) was added 24 h after
transfection.
Promoter-reporter assays
Cell extracts were prepared 48 h after transfection and 60 gg of
the cell extract was incubated with 14C-chloramphenicol in the
presence of acetyl CoA at 37 °C as described previously (25). The
percentage acetylation of chloramphenicol was quantitated by
separating the acetylated products by thin-layer chromatography,
visualized by autoradiography, and quantitated by scintillation
counting of excised spots or by scanning on a Molecular
Dynamics Phosphorlmager.
Constmction of RXRa mutants
The 3' deletion mutants of RXRa were constue by linarizing
pBSRXRa with StuI (1463) (deletes 36 amino acids) BssHII (1185)
(deletes 66 amino acids) or with BamHI (777) (deletes 227 amino
acids). Mutants spanning the region between BssHl and BamHI
were obtained by PCR amplification with a5' primer containing the
T7 promoter sequence 5'-CITCGAGAATTGTAATACGACTCAC-
TATAGGG-3' and 3' primers at different positions as follows:
5'-CTCGAGCCCTGTCAAAGATGGCGCCC-3' (1101), 5'-CTC-
GAGGGGAGAAGGAGGCGATGY;AGCA-3' (999) and 5'-CTCG-
AGCTCCACCAGGGTGAAAAGC-3' (899). The template was a
gel-purified DNA fragment of pBSRXRa containing the intact
RXRa ORF downsteam of the T7 promoter. The PCR products
were gel-purified and then used in in vitro transcription-translations
to make a 35S-methionine-labeled protein.
DNA-binding studies
A 17 bp oligonucleotide containing the AP1 sequence was
end-labeled with the use of T4 polynucleotide kinase and
['-32P]ATP and used as probe for binding with in vitro-translated Z
or Z mutants for 20 mi at room temperatr. Binding ractions
were performed in buffer contining 250 mM Hepes, pH 7.9, 700
mM KCl, 5 mM EDTA, 10mMDTT and 5% NP-40. Protein-DNA
complexes were resolved by PAGE on 5% gels in 0.5 x TBE (1 x
TBE + 0.09 M Tris-borate/0.002 M EDTA ) and the dried gel was
exposed with an intensifying screen at -70°C on Kodak XAR film.
RESULTS
Retinoic acid receptors RARa and RXRa bind to the
dimerization domain of Z
We have shown that RARa and RXRa are repressors of
Z-mediated transactivation of the EBV early promoter, BMRF- 1.
RXRa interferes with Z binding to the BMRF1 promoter and,autoradiography.


















U) ) u)o CO CD o
RXR......
* :





1 2 3 4 5
Figure 1. Dimerization domain of Z is required for the interaction with RXRo
and RARca. (A) For dimerization experiments, 35S-labeled RARa protein
(10 000 c.p.m.) was incubated with GST-fusion proteins bound to beads in
reaction buffer (10mM Tris, pH 8.0, 40 mM KCl, 0.05% NP-40, 6% glycerol,
1 mM DTT, 0.2 gg poly dI/dC) for 1 h at 37°C, washed, pelleted and boiled in
Laemmli buffer. Bound proteins were resolved on SDS/10% PAGE and
visualized by autoradiography. The arrow indicates the position of 35S-labeled
RARa protein retained by GST protein alone (lane 1) or GST-fusion proteins,
GST-Z (lane 2), GST-ZA 1-86 (lane 3), GST-ZA 140-227 (lane 4) and GST-ZA
200-227 (lane 5), GST-Z (lane 2) or GST-RXRa (lane 3). (B) The same
GST-fusion proteins were incubated with the beads and then incubated with
35S-labeled RXRax as described above.
reciprocally, Z interferes with the binding of RXRx to its
consensus binding site, aRARE sequence in the cellular promoter
for RARP (17). Here we test by affinity chromatography whether
RARoc and RXRax interact directly with GST-Z fusion protein. In
vitro-translated 35S-methionine-labelled RARax bound to beads
coated with GST-Z (Fig. 1, lane 2), but not to the GST protein
alone (lane 1). A mutant of Z, which retains only its DNA-binding
and dimerization domain (ZA 1-86, lane 3), could still retain
RARoc whereas fusion proteins containing deletions in the
coiled-coiled dimerization domain of Z (ZA 140-227 and ZA
200-227, lanes 4 and 5) could not. Similarly, labeledRXRabinds
to GST-Z (lane 2) and to ZA 1-86 (lane 3) but not to the mutants
of Z that have the dimerization domain deleted (lanes 4 and 5) as
shown in Figure lB. These results suggested that either RXRat
and RARax interact within a region of Z corresponding to amino
acids 140-227 or that homodimerization of Z is required for
interaction with RXRa and RARax.
Z binds to RXRax in a region that is not required for
homodimerization of Z
To define further the region of Z within the dimerization domain
(Fig. 2A) that was required for interaction with RXRx, point
mutants of Z (a generous gift from E. Flemington) were
radiolabelled (as shown in Fig. 2B) and equal amounts of labeled
protein used in affinity-chromatography experiments. These
experiments led to the identification of mutants of Z that
differentially bound to GST-Z and not to GST-RXRa. The
wild-type Z protein bound well to GST-Z (Fig. 2C, lane 2) and
GST-RXRa (lane 3) but not to GST alone (lane 1). Two mutants
of Z (Z214R/218S and Z214S/218S) that cannot form Z
homodimers in glutaraldehyde-crosslinking assays and did not
bind to GST-Z (lanes 8 and 10), also did not bind to RXRa (lanes
9 and 11) suggesting that a dimer of Z may be required for this
interaction. Both these mutations are at the interface of the
predicted Z coiled-coiled homodimer. Another mutant
(Z209R/216E), with mutations introduced in residues predicted
to be on the back of the helix binds to GST-Z (lane 12) as expected
and also interacts with GST-RXR(x (lane 13). Furthermore, a
protein with mutations of two alanine residues also predicted to
be at the back of the helix (Z205R/206D, lane 6) could interact
with Z. However, this mutant could not bind to RXRax (lane 7),
identifying a region in Z not needed for homodimerization but
likely to be involved in its interaction with RXRax. Surprisingly,
two Z mutants predicted not to dimerize based on glutaraldehyde-
crosslinking studies (26) (Z197K/200S and Z200E/225E) could
still interact with GST-Z in the GST-affinity chromatography
assays (lanes 4 and 14), but were unable to interact with
GST-RXRoc (lanes 5 and 15). The results suggest that preserva-
tion of a core Z homodimerization domain is needed for
interaction with RXRax. However the subdomain of Z that
governs the ability to homodimerize may be different from that
required to bind to RXRa. Thus we have identified three mutants
of Z that could interact with GST-Z but not with GST-RXRa.
DNA-binding by Z mutants
To determine if the Z point mutants could bind to a Z-DNA
binding site, we used the in vitro-transcribed and translated
proteins in electrophoretic mobility shift assays. A 32P-labeled 17
bp oligonucleotide containing the API site was incubated with
wild-type or mutant Z proteins. As shown in Figure 3, wild-type
Z binds to the API site (lane 2), and addition of cold API
oligonucleotide competes for this binding (lane 1). Mutants
(Z205R/206D, 200E/225E and Z209R/216E) that can still
dimerize to Z bind to the API site as well as the wild-type Z,
whereas Z197K/200S, which also homodimerizes, does not bind
to DNA as well. Mutants Z214R/218R and 214S/218S do not
bind to DNA.
Mutants of Z that retain the transactivation function
but not the repressor function
When a construct containing the RARI promoter (BRE-CAT) is
co-transfected with any of the retinoic acid receptors (RARca, Y
and RXRa) in the presence of RA, there is an increase in the
promoter activity. We have shown that when the same promoter
is co-transfected with these RARs and Z, promoter activity is
completely inhibited (17 and Fig. 4A) and that inhibition is due
to a direct interaction of the two proteins which results in Z
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Ns = N z Figure 3. DNA-binding of Z mutants. Wild-type (lanes 1 and 2) or mutant Z
proteins Z197K/200S (lane 3), Z205R/206D (lane 4), or 200E/225E (lane 5),
Z214R/218R (lane 6), 214S/218S (lane 7) and Z209R/216E (lane 8) were
transcribed and translated in vitro and incubated with radiolabelled DNA probe
*_+ z containing an intact API site in reaction buffer as described in Materials and
Methods.
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Fgu 2. Interaction of Z mutants with RXRa. Protein binding experiments
were done using Z mutants having point mutatons within the dimerization
domain ofZ as described. (A) Schematic diagram of the functional domains of
Z and location of the mutations. (B) Wild-type (lanes 1-3) or mutantZ proteins
that homodimerize, Z197K/200S (lanes 4 and 5), Z205R/206D (lanes 6 and 7),
209E/216E (lanes 12 and 13) or 200E/225E (lanes 14 and 15) or mutants that
did not homodimerize, Z214R/218R, Z214S/218S (lanes 8-11) were tran-
scribed and translated in vitro using 35S-methionine and analyzed on a 10%
SDS/PAGE. (C) Proteins were incubated with eitier GST alone, or GST-Z or
GST-RXRa fusion proteins attached to GST-Sepharose beads, washed and
boiled samples analyzed on a 10% SDS/PAGE.
interfering with the binding of RARa to its cognate site in the
promoter. To complement these in vitro studies we tested whether
mutants ofZ that were unable to bind toRXRa in vitro would no
longer interact with RXRa in the cell as indicated by inability to
down-regulate an RXRa-responsive promoter. BRE-CAT was
co-transfected with expression clones of RXRa and each of the
Z mutants into EBV- lymphoblastoid cells (Louckes) and treated
with RA (1 iM) 24 h before harvesting. Repression of
RXRa-mediated activity by wild-type Z protein was considered
to be 100% (Fig. 4B, bar 1). Z protein with a deletion in the
transactivation domain ofZ (ZA 25-29) or Z209R/216E can still
repress >90% of the activity (bars 2 and 10). However, when
mutants that did not bind to RXRa in vitro such as Z197K/200S
(bar 5) were co-transfected with RXRa, only a 22% repression of
activity resulted. Similarly, co-transfection of Z205R/206D (bar
6) and Z200E/225E (bar 7) with RXRa (neither mutant binds to
RXRa) had less effect repressing only 30 and 18%, respectively,
of promoter activity. Z mutants (Z214R/218S and Z214S/218S)
(bars 8 and 9) that interacted with neither Z norRXRa could not
repress transactivation ofBRE-CAT by RXRoc The plasmids ZA
140-227 (bar 3) and ZA 200-227 (bar 4) serve as negative
controls, since theZ protein expressed from these constructs does
not contain its nuclear localization signal. Thus the mutants ofZ
that could not bind to RXRa in vitro could not repress
RXRa-mediated transactivation in vivo.
To test further whether the in vitro results correspond with
interactions in vivo we used mutants that could homodimerize
(Z197K/200S, Z205R/206D, Z200E/225E and Z209R/216E);
these mutants can transactivate the Z-responsive EBV early
promoter, BMRF1. As shown in Figure 5, co-transfection of the
BMRF1-CAT construct with Z results in -70-fold increase in
activity (bar 1). Co-transfection of Z197K/200S (bar 2) can still
induce at least 28-fold increase in activity, and Z205E/206D (bar
3), Z200E/225E (bar 6) andZ209R/216E (bar 7) can transactivate
as well as and sometimes better than wild-type Z corroborating
the in vitro results. In contrast, Z214R/218S and Z214S/218S
(bars 4 and 5), which did not interact with wild-type GST-Z in
vitro, could not transactivate BMRF1-CAT.
Mapping of the RXRa domain required for interaction
with Z
Steroid hormone receptors including RARs/RXRs have a tripar-
tite modular structure. The receptors have three identified
domains: transactivation, DNA-binding and ligand-binding. The
ligand-binding domain encompasses amino acids 240-462 at the
C-terminus. Studies of dimerization with RXRa and interactions
with other proteins suggested that the homodimerization domain
of RXRa was in the C-terminus of the protein spanning amino
acids 415-462 (27-31). We tested a series of C-terminal-trun-
cated proteins that were expressed as described in Materials and
Methods (Fig. 6A). As shown in Figure 6B, wild-type RXRa
binds just as well to GST-Z (lane 2) as to GST-RXRa (lane 3). A
mutant protein containing deletions of 60 amino acids in the
C-terminus of RXRa also binds well to GST-Z (lane 4) and
weakly to GST-RXRa (lane 5). RXRa with 92 amino acids
deleted can be retained by GST-Z (lane 6) but weakly if at all by
GST-RXRa (lane 7). RXRa mutants with 122 or more amino
A
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Figure 4. Effect ofZ mutants on RXRa-mediated transactivation of the cellular
promoter for RAR,B. (A) The BRE-CAT construct was transfected into
EBV-negative lymphoid cells, (Louckes) and co-transfected with pHD1O13
(bar 1) or expression clones of wild-type Z protein (bar 2). (B) The BRE-CAT
was also co-transfected with pHD1013, Z (barl) or a protein with a mutation
in the transactivation domain Z (ZA 25-29, bar 2), a protein with the
leucine-zipper deleted (ZA 200-227, bar 3), a protein with 87 amino acids
deleted from the dimerization domain ofZ (ZA 140-227, bar4) orpoint mutants
that did not interact with RXRa, Z197K/200S (bar 5), Z205R/206D (bar 6),
Z200E/225E (bar 7), Z214R/218R (bar 8), Z214S/218S (bar 9) and
Z209R/216E (bar 10) as indicated. The cells were starved for 24 h before
transfection, and RA (1 gM) was added 24 h after transfection. The promoter
activity was assayed as described in Materials and Methods.
acids deleted from the C-terminus (lanes 8-15) had drastically
reduced ability to bind to GST-Z or GST-RXRax. Therefore the
domain ofRXRa that interacts with Z seems to be separate from
its homodimerization domain.
DISCUSSION
The EBV immediate-early protein, Z, is sufficient to trigger
disruption of viral latency. Z, a member of the b-Zip family of
proteins, forms homodimers and transactivates EBV early
promoters containing cis-acting elements (ZREs) that start a
cascade of events resulting in viral reactivation. Latency is almost
certainly largely governed by cellular factors, and negation of
leaky Z function would be necessary to maintain it. Retinoic acid
receptors are excellent candidates for such regulatory cellular
factors since they affect the status of cell differentiation which is
important for different EBV infection states. Here we show that
the reciprocal effects ofretinoic acid receptors and Z in repressing
activation of viral and cellular promoters are based on direct
physical interaction between Z and RXRa. Mapping of the
regions ofZ and RXRx that are involved shows that RXRa binds
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Figure 5. Effect ofZ mutants on transactivation of the EBV BMRFI promoter.
The BMRF1-CAT construct was transfected into EBV-negative lymphoid cells
(Louckes), and co-transfected with expression clones of wild-type Z protein
(bar 1) or point mutants, Z197K/200S (bar 2), Z205R/206D (bar 3),
Z200E/225E (bar 4), Z214R/218R (bar 5), Z214S/218S (bar 6) and
Z209R1216E (bar 7). The cells were starved in charcoal-stripped serum for 24
h before transfection. Promoter activity was assayed as before.
to Z within its dimerization domain (Fig. 1A). Furthermore,
RARa also directly interacts with Z in vitro (Fig. LB).
The Z protein functions as a coiled-coiled dimer (26).
However, within this domain the region required for interaction
with RXRa is distinct from that required for interaction with
itself, as illustrated by the mutant Z205R/206D that can still bind
to GST-Z but does not bind to RXRa (Fig. 2). The results differ
from earlier results indicating that Z200E/225E could not form
homodimers; here we show that this mutant can bind to GST-Z.
Furthermore this mutant can bind to DNA (Fig. 3) and can
transactivate a Z-responsive promoter (Fig. 5). The mutant DNA
clones were confirmed by DNA sequencing. It is possible that
these differences in the dimerization potential of the mutant Z
proteins were detected because of the two different methods of
analysis. Glutaraldehyde-crosslinking may not be as sensitive as
GST-Z affinity chromatography. In our hands these mutants
homodimerize well. It is also possible that the GST-Z fusion
protein stabilizes the interaction with some of the mutants and
thus binds to them under certain temperature and reaction
conditions. However, the DNA-binding capacity of the mutants
and the fact that these mutants can transactivate the BMRF1 -CAT
promoter construct in lymphoid cells as well as wild-type Z make
a definitive case.
Point mutants ofZ that differentially bind to Z but not to RXRat
can be explained by the model shown in Figure 7. Z homodimers
(or multimers) may present an interface for interaction with
RXRax to form a higher order complex that is disrupted in Z
mutants exemplified by Z205R/206D. Therefore these mutants
can still homodimerize but can not bind to RXRax. Part of this
interface may overlap with the dimerization interface, or there
may be a change in conformation, so that mutants like
Z197K/200S that dimerize well in this assay may not form dimers
under some conditions. Mutants like Z209R/216E may be able to
dimerize under both conditions, perhaps because the mutation is
not in the interface presented to the receptor or the interface
required for homodimerization. On the other hand, mutant
Z214R/218R cannot homodimerize and therefore cannot present
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Figure 6. Interaction of RXRa mutants with Z. (A) The 3' deletion mutants ofRXRa were constructed by linearizing pBSRXRa with Stul (1463), A425, (lanes 4
and 5) deleting 60 amino acids, BssHII (1185), A395, deleting 92 amino acids, or with BamHI (777), A258, deleting 257 amino acids. Mutants spanning the region
between BssHII and BamHI were obtained by PCR amplification as described in Material and Methods. IThe PCR products were gel punfied and used in in vitro
wanscription andtranlation using 35S-methionine. (B) Equal amounts ofradiolabelled mutantRXRa proteins were incubated with GST-Z orGST-RXRa and analyzed
using SDS/PAGE.
an interface for interaction with dimers or multimers ofRXRa to
form a higher order complex.
The identification ofZ mutants that differentially bind to Z and
not RXRa enabled probing for effects of interaction between Z
and RXRa in cells. Mutants of Z that did not bind to RXRa in
vitro were incapable of repressing RXRa-mediated transactiva-
tion in vivo (Fig. 4). In contrast, these mutants could form
homodimers and could transactivate the Z-responsive promoter
as well as wild-type Z; Z mutants tat did not homodimerize
could not activate the promoter (Fig. 5). On the other hand, a
mutant (Z197K1200S) which could not bind to DNA well could
still transactivate the Z-responsive promoter, but transactivation
was very variable and never as much as with wild-type Z. It has
been reported that Z may have a tansactivation function
independent of DNA binding. Several groups have provided
evidence that non-DNA binding forns of Z may be generated
post-transcriptionally (32). Mutant Z proteins that cannot bind
DNA have been shown to transactivate Z-responsive promoters.
Transactivation by such Z mutants may be mediated through
interaction with cellular transcription factors. Such DNA-binding
mutants ofZ can activate tanscription through acAMP-response
element (CRE) and NF-wiB sites but not through ZREs or API
(33). Perhaps Z197K/200S falls into this category of mutants and
further characterization will be interesting.
Negative regulation by retinoic acid receptors is mediated
through very different mechanisms, some of which involve a
protein-protein interaction (20,21,34,35). Although RARa has
been shown to inhibit DNA-binding of AP1, this is a demonstra-
tion of a physical interaction between a member of the steroid
hormone family, which has a zinc-finger motif, andthe leucine-
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Figure 7. Physical interaction between RXRa and Z. A hypothetical model
depicting the possible interactions between Z and RXRa. The wild-type Z
dimers or multimers may present an interface for interaction with RXRa to
form a higher order complex. In mutants like Z205R/206D, the interface may
be disrupted although homodimerization ofZ is still possible. In other mutants
such as Z214R/218R, homodimers cannot be formed and thus do not allow the
formation of the interface.
zipper-containing Z protein, which belongs to the b-Zip family.
Mapping of the RXRax domain required for interaction has
indicated that Z binds to an internal region of the ligand-binding
domain of RXRa. The E region of the receptors is required for
homodimerization ofRXRa and heterodimerization with retinoic
acid receptor (RAR) and thyroid hormone receptor (TR) (27-31).
Forman and Samuels proposed that the ligand-binding domain
encompasses nine short hydrophobic heptad regions (30). The
ninth C-terminal heptad is required for the heterodimerization of
RXRa with other members of the receptor family such as RAR
and TR (36). In contrast, both vitamin D3 receptor (VDR) and
peroxisome-proliferator-activated receptor (PPAR) require addi-
tional N-terminal RXR sequences for heterodimerization (37).
Although deletion of the C-terminal 40 amino acid segment from
the ligand-binding domain of RXRa abolishes the interface for
heterodimerization, homodimerization may require the region
spanning amino acids 415-425. The DNA-binding domain also
presents an interface for stable homodimer formation (38). The
results indicate that the loss of the C-terminal 60 amino acids of
RXRa, which deletes the ninth heptad but contains the DNA-
binding domain, binds weakly to a GST-RXRa fusion protein as
expected. However, loss of additional amino acids abolishes the
ability of mutant RXRa to bind to GST-RXRa.
Interestingly, Z binds to RXRA401 (a mutant lacking the ninth
heptad), indicating that the heterodimerization domain of RXRat
may not be a target for Z interaction. Other members of the
receptor family compete for the same interface of RXRa for
heterodimerization, and therefore overexpression of one may
result in repression of transactivation by another receptor. For
example, since TR and RARa bind to the same interface of
RXRa, overexpression of TR has been shown to repress
RARa-mediated transactivation (36). These results suggest that
Z does not compete with other members of the steroid hormone
receptor family for binding to RXRa. Presumably repression of
RXRa and RARa-mediated transactivation is due to direct
interaction in a region different from that required for homo- or
heterodimerization. Rather it is possible that Z dimers or
multimers interact with RXRa homo- or heterodimers or
multimers to form a higher order complex.
The potential to form homo- and heterodimers or higher order
complexes among the members of the nuclear steroid hormone
superfamily within the cell imparts increased diversity and
versatility on the function of the nuclear receptors and thereby on
nuclear hormones. Such combinatorial mechanisms also operate
within families of transcription factors, including members of the
leucine-zipper family and the c-rel oncogene family which allows
fine tuning of regulation of gene expression (39,40). Intranuclear
communication also occurs between members of two distinct
families of transcription factors, adding another level of regula-
tion. Such cross-talk has been detected between members of the
API family and nuclear receptors (22,35,41) or API and the rel
family (14,42) or, more recently, between the rel family and
nuclear receptors (43). Viruses are dynamic participants in this
intricate circuitry of signals in the cell. It is not surprising then that
RARs transactivate the hepatitis B virus enhancer I (44) and
initiate induction of the cytomegalovirus enhancer in embryonal
cells (45). In contrast, RA has been shown to repress the
expression of human papillomavirus 18 E6/E7 genes (46). The
interaction between the EBV protein, Z, and RXRa provides an
example of communication not only between members of
different transcription factor families, but also between the viral
and cell factors.
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